Author | No. of patients | Disease | Activation motif of CAR | Dose of infused CAR-T | No. of GVHD | Toxicities | Outcomes |
---|---|---|---|---|---|---|---|
Kochenderfer et al. | 10 | CLL, DLBCL, and MCL | 28 | Between 0.4 × 106/kg and 7.8 × 106/kg | No | Fatigue, fever, and hypotension | 1 CR, 1 PR, and 6 with stable disease |
Cruz et al. | 8 | CLL and ALL | 28 | Escalation schedule of 1.5 × 107/m2, 4.5 × 107/m2, and 1.2 × 108/m2 | No | No | 2 CR(1 remained in CR for 8 months and the other 1 for 8 weeks) |
Brudno et al. | 20 | CLL, DLBCL, MCL, and ALL | 28 | From 106/kg to 107/kg | 2 (mild chronic GVHD) | Fever, tachycardia, and hypotension | 8 of 20 patients obtained remission (6 CR and 2 PR) |
Zuo et al. | 1 | ALL | 28, 137, and 27 | First dose 106/kg and three maintenance (from 0.83 × 106 to 1.65 × 106/kg) | No | Mild or moderate CRS | DFS for 10 months |
Grupp et al. | 1 | ALL | 28 | 1.4 × 106/kg | No | Fever | MRD-negative CR at approximately 1 month and relapse after 2 months |